Linked Life Data

12689948

Source:http://linkedlifedata.com/resource/pubmed/id/12689948

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2003-8-5
pubmed:abstractText
Hepatitis C virus (HCV) may be associated with the mixed cryoglobulinemia syndrome and other B-cell lymphoproliferative disorders (LPDs). The t(14;18) translocation may play a pathogenetic role. Limited data are available regarding the effects of antiviral therapy on rearranged B-cell clones. We evaluated the effects of interferon and ribavirin on serum, B-lymphocyte HCV RNA, and t(14; 18) in 30 HCV+, t(14;18)+ patients without either mixed cryoglobulinemia syndrome or other LPDs. The t(14;18) translocation was analyzed by both bcl-2/JH polymerase chain reaction and bcl-2/JH junction sequencing in peripheral blood mononuclear cells in all patients. Fifteen untreated patients with comparable characteristics served as controls. Throughout the study, the presence or absence of both t(14;18) and HCV RNA sequences were, in most cases, associated in the same cell samples. At the end of treatment, t(14;18) was no longer detected in 15 patients (50%) with complete or partial virologic response, whereas it was persistently detected in nonresponders (P <.05), as well as in 14 of 15 control patients. In 4 responder patients, t(14;18) and HCV RNA sequences were no longer detected in blood cells after treatment, but were again detected after viral relapse; the same B-cell clones were involved in the pretreatment and posttreatment periods. In conclusion, this study suggests that antiviral therapy may induce regression of t(14;18)-bearing B-cell clones in HCV+ patients and that this phenomenon may be related, at least in part, to the antiviral effect of therapy. This in turn suggests that antiviral treatment may help prevent or treat HCV-related LPDs.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
0006-4971
pubmed:author
pubmed:issnType
Print
pubmed:day
15
pubmed:volume
102
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1196-201
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:12689948-Alanine Transaminase, pubmed-meshheading:12689948-Antiviral Agents, pubmed-meshheading:12689948-B-Lymphocytes, pubmed-meshheading:12689948-Base Sequence, pubmed-meshheading:12689948-Chromosomes, Human, Pair 14, pubmed-meshheading:12689948-Chromosomes, Human, Pair 18, pubmed-meshheading:12689948-Drug Therapy, Combination, pubmed-meshheading:12689948-Female, pubmed-meshheading:12689948-Genes, bcl-2, pubmed-meshheading:12689948-Hepatitis C, Chronic, pubmed-meshheading:12689948-Humans, pubmed-meshheading:12689948-Interferons, pubmed-meshheading:12689948-Male, pubmed-meshheading:12689948-Middle Aged, pubmed-meshheading:12689948-Molecular Sequence Data, pubmed-meshheading:12689948-RNA, Viral, pubmed-meshheading:12689948-Ribavirin, pubmed-meshheading:12689948-Translocation, Genetic, pubmed-meshheading:12689948-Treatment Outcome
pubmed:year
2003
pubmed:articleTitle
Effect of antiviral treatment in patients with chronic HCV infection and t(14;18) translocation.
pubmed:affiliation
Department of Internal Medicine, University of Florence, School of Medicine, Italy.
pubmed:publicationType
Journal Article, Clinical Trial, Comparative Study, Controlled Clinical Trial, Research Support, Non-U.S. Gov't